Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR1 Peptide Vaccine in AML in Remission
NCT00454168Phase 3Unknown
- Sponsor
- Vaccine Company
- Start
- May 2005
- Primary completion
- Apr 2009
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PR1 leukemia peptide vaccine in acute myeloid leukemia (AML) (2 arms), sponsored by Vaccine Company. Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
PR1 leukemia peptide vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00454168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454168.